• Home

Home > Medical Reference > Patient Education

• Highlights
• Introduction
• Causes
• Symptoms
• Risk Factors
• Lifestyle Changes
• Diagnostic Tests
• Complications
• Staging Systems
• Surgical Procedures
• Radiation Treatments
• Treatment Options by Stages
• Chemotherapy Treatments
• Investigative Agents
• Resources
• References

Non-small cell lung cancer

Description

An in-depth report on the causes, diagnosis, treatment, and prevention of non-small cell lung cancer (NSCLC).

Alternative Names

Lung cancer -  non-small cell; NSCLC

Staging Systems

Tests to Determine Cancer Stage. After diagnosing non-small cell lung cancer, the doctor makes treatment choices by determining the cancer's stage (how large the tumor is and how far the cancer has spread). To stage the cancer and determine other aspects of the disease, a number of tests are conducted:

• The cancer cells are examined microscopically for size, shape, and other configurations.
• Computer tomography (CT), magnetic resonance imaging (MRI), or both, are used to scan the lung and perhaps other locations, such as the liver, upper abdomen, and brain, to determine the extent of the disease.

Physical Examination. A detailed physical examination of the whole body is very important to identify or rule out the spread of cancer to other areas, and to determine the general condition of the patient. For example, questions about dizziness or headaches can help the doctor determine if the cancer has spread to the brain, while bone or joint pain might suggest that the cancer has spread to the bone. The doctor will also look for head and neck symptoms that might reveal the presence of other tumors. Also, according to a 2000 review, the patient's weight loss and ability to function are two very important factors for predicting survival following treatment. Patients who are mobile and have lost less than 10% of their pre-treatment weight tend to have better survival rates.

Staging Systems

In lung cancer, the stage of the disease at the time of diagnosis is a major factor in determining how to treat the cancer, and how long the patient can expect to live. In general, survival is longest for patients with very early-stage disease and shortest for patients with very advanced disease that has spread to several regions of the body. Staging is based on the results of physical and surgical examinations, and laboratory and imaging tests, including biopsies.

• To determine the stage, medical professionals first categorize each tumor by size and by how far it has extended. This identification method is called the TNM system.

The TNM categories then determine the stage (numbered 0 to IV), which indicates how advanced the cancer is.

The TNM System TNM stands for T umor, regional lymph N odes, and M etastasis (cancer spread beyond the original tumor). T refers to the size and extension of the tumor itself. In TX and T0, the tumor is indicated by cancer cells in sputum or lung samples but cannot be seen. Tis: Carcinoma in situ. The cells are cancerous, but the tumor does not show evidence of spreading. In T1, the tumor is 3 cm or less in size, is still contained in the lung or the membrane covering the lung, and has not reached the main airway. In T2, the tumor has one or more of the following features: It is greater than 3 cm It involves the main airway It is 2 cm or more away from the ridge (the carina) at the lowest part of the windpipe (trachea) It has invaded the pleura It is associated with collapsed lung tissue (atelectasis) or swelling that blocks part (but not all) of the lung In T3, a tumor of any size has directly invaded any of the following: Chest wall Diaphragm The membrane covering organs and structures in the chest The outer wall of the membrane around the heart (pericardium) In addition, one or more of the following conditions are present: The tumor is in the main airway, less than 2 cm away from the carina, but is not in the trachea. The tumor is associated with a collapsed lung or swelling that blocks the entire lung. In T4, the tumor has invaded any of the following: The area between the lungs (mediastinum) The heart The great vessels (the blood vessels that carry blood from the heart) Carina, trachea, or esophagus Main portion of the spine In addition, one or both of the following: separate tumor nodules are present in the same lobe; the tumor is accompanied by an increased amount of fluid between the membrane and the lung. N followed by a number from 0 to 3 refers to whether the cancer has reached regional (in the area of tumor) lymph nodes. In stage N0, the regional lymph nodes are still cancer-free. In N1, the cancer has spread to the nearest lymph nodes around the airways, the hilum (a central zone in the lung where blood and lymph vessels enter), or both. The tumor has extended directly into lymph nodes within the lung. In N2, the cancer has spread to lymph nodes in the middle of the chest that are still next to the affected lung, to the nodes below the carina, or to both regions. In N3 the cancer has spread to lymph nodes in the middle of the chest that are next to the opposite lung, to the hilum in the opposite lung, to lymph nodes in nearby or opposite muscle tissue, or to lymph nodes above the collar bone. Stages M refer to metastasis. In M0, metastasis has not occurred. In M1 distant metastasis has occurred. This includes the presence of a separate tumor in a different lobe.

Other Factors Determining Treatment Choices and Outcome

Staging factors are used to help determine treatment and outlook. The following suggest a more aggressive disease:

• The presence of respiratory symptoms
• A tumor larger than 3 cm
• High numbers of blood vessels in the tumor

Researchers are always looking for more accurate ways to determine a treatment and outlook for lung cancer. For example, some research involves specific biomarkers and related blood vessel development within tumors. These markers might eventually help determine how aggressive a cancer is likely to be, and what the best treatment approach is.

General Treatment Approach After Staging

If the cancer is still localized, surgery can produce five-year survival rates of up to 75% in stage I patients and up to 50% in stage II patients. Unfortunately, very few patients are diagnosed at such early stages. In locally advanced stages, the standard treatment is concurrent radiation and chemotherapy. However, even with this approach average survival times are less than two years. Even if an initial tumor has been surgically removed or irradiated, cancer recurrence rates are very high. The risk for recurrence is lower in smokers who quit after treatment.

On an encouraging note, advances in therapies for later stage lung cancer are now offering some hope for improving survival. Still at this time, the mortality rate for lung cancer is still extremely high, and reports of improved response or survival rates using drugs or combinations therapies do not mean cures. Ultimately, the patient must weigh a diminished quality of life using some aggressive treatments against a chance for a modestly prolonged life.

• Review Date: 6/30/2006
• Reviewed By: Harvey Simon, MD, Editor-in-Chief, Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.